You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial

Article metrics

Article menu

Download PDFPDF

XML
Pharmacology and therapeutics
Protocol
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial

 

Online download statistics by month:

Online download statistics by month: May 2020 to April 2024

AbstractFullPdf
May 2020471388115
Jun 2020278228158
Jul 202032626686
Aug 202041433672
Sep 2020420328121
Oct 2020456365115
Nov 202043831183
Dec 202056349197
Jan 2021451353127
Feb 2021375278105
Mar 2021504377165
Apr 2021458339133
May 2021377265143
Jun 2021382227136
Jul 2021385300130
Aug 2021363280103
Sep 2021356260128
Oct 2021390291132
Nov 2021372245125
Dec 2021367268129
Jan 2022394303107
Feb 2022369292170
Mar 2022462392177
Apr 2022362268110
May 2022373303145
Jun 2022286216108
Jul 202228620758
Aug 202239630582
Sep 2022470370109
Oct 2022561427132
Nov 2022428331116
Dec 202237827280
Jan 202342225087
Feb 2023422268133
Mar 2023508290126
Apr 202337821564
May 2023363208123
Jun 202328614073
Jul 202333217084
Aug 202336220575
Sep 202335419073
Oct 202347526294
Nov 2023459241106
Dec 202338317480
Jan 202431415775
Feb 202429115583
Mar 2024294227130
Apr 202418813285
Total18742131665288